Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
27568522
DOI
10.1038/leu.2016.246
PII: leu2016246
Knihovny.cz E-zdroje
- MeSH
- analýza přežití MeSH
- chronická myeloidní leukemie diagnóza epidemiologie terapie MeSH
- dospělí MeSH
- incidence MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- následné studie MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- registrace MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- surveillance populace MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1+ chronic myeloid leukemia (CML) in 20 predefined countries and regions of Europe. Registration time ranged from 12 to 60 months between January 2008 and December 2013. Median age was 55 years and median observation time was 29 months. Eighty percent of patients were treated first line with imatinib, and 17% with a second-generation tyrosine kinase inhibitor, mostly according to European LeukemiaNet recommendations. After 12 months, complete cytogenetic remission (CCyR) and major molecular response (MMR) were achieved in 57% and 41% of patients, respectively. Patients with high EUTOS risk scores achieved CCyR and MMR significantly later than patients with low EUTOS risk. Probabilities of overall survival (OS) and progression-free survival for all patients at 12, 24 and 30 months was 97%, 94% and 92%, and 95%, 92% and 90%, respectively. The new EUTOS long-term survival score was validated: the OS of patients differed significantly between the three risk groups. The probability of dying in remission was 1% after 24 months. The current management of patients with tyrosine kinase inhibitors resulted in responses and outcomes in the range reported from clinical trials. These data from a large population-based, patient sample provide a solid benchmark for the evaluation of new treatment policies.
3 Medizinische Klinik University of Heidelberg at Mannheim Mannheim Germany
Abteilung Hämatologie Onkologie Klinik für Innere Medizin 2 Universitätsklinikum Jena Jena Germany
Clinic of Hematology CCS and Faculty of Medicine University of Belgrade Belgrade Serbia
Department Hemato oncology University Hospital Olomouc Olomouc Czech Republic
Department of Haematology VU University Medical Center Amsterdam The Netherlands
Department of Hematology and Transplantation Medical University of Gdansk Gdansk Poland
Department of Hematology University Clinical Centre Ljubljana Slovenia
Department of Hematology University Hospital Bratislava Slovakia
Department of Oncology and Hematology Hematology Unit St Orsola University Hospital Bologna Italy
Division of Hematology AOU Policlinico OVE University of Catania Catania Italy
INSERM CIC 1402 CHU Poitiers Poitiers France
Katedra i Klinika Hematologii UJCM Kraków Poland
Klinikum Wells Grieskirchen Wells Austria
Munich Cancer Registry Ludwig Maximilians Universitaet Munich Germany
Riga East Clinical University Hospital Riga Latvia
Royal Liverpool University Hospital Liverpool UK
Servicio de Hematología Hospital Virgen de la Salud Toledo Spain
St Petersburg State Medical University St Petersburg Russian Federation
Tartu University Hospital Tartu Estonia
The Karaiskakio Foundation Nicosia Cyprus
University of Bologna Bologna Italy
University of Uppsala Uppsala Sweden
Vilnius University Hospital Santariskiu Klinikos and Vilnius University Vilnius Lithuania
Citace poskytuje Crossref.org
